U
14.20
0.42 (3.05%)
| Previous Close | 13.78 |
| Open | 14.00 |
| Volume | 1,017,054 |
| Avg. Volume (3M) | 1,114,973 |
| Market Cap | 767,891,968 |
| Price / Earnings (Forward) | 27.93 |
| Price / Sales | 22.43 |
| Price / Book | 2.83 |
| 52 Weeks Range | |
| Earnings Date | 27 Feb 2025 |
| Operating Margin (TTM) | -796.27% |
| Diluted EPS (TTM) | -4.92 |
| Quarterly Revenue Growth (YOY) | -21.90% |
| Total Debt/Equity (MRQ) | 889.83% |
| Current Ratio (MRQ) | 9.74 |
| Operating Cash Flow (TTM) | -182.73 M |
| Levered Free Cash Flow (TTM) | -139.79 M |
| Return on Assets (TTM) | -16.39% |
| Return on Equity (TTM) | -238.46% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | uniQure N.V. | Bullish | Bullish |
AIStockmoo Score
0.4
| Analyst Consensus | 3.0 |
| Insider Activity | 0.0 |
| Price Volatility | -4.5 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 2.0 |
| Average | 0.40 |
|
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 8.59% |
| % Held by Institutions | 77.64% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Integral Health Asset Management, Llc | 31 Dec 2024 | 1,100,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 70.00 (HC Wainwright & Co., 392.96%) | Buy |
| Median | 30.00 (111.27%) | |
| Low | 24.00 (RBC Capital, 69.01%) | Buy |
| Average | 41.33 (191.06%) | |
| Total | 2 Buy, 1 Hold | |
| Avg. Price @ Call | 13.13 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 04 Mar 2025 | 70.00 (392.96%) | Buy | 11.33 |
| 27 Jan 2025 | 70.00 (392.96%) | Buy | 15.80 | |
| Wells Fargo | 28 Feb 2025 | 30.00 (111.27%) | Hold | 13.15 |
| RBC Capital | 21 Jan 2025 | 24.00 (69.01%) | Buy | 14.91 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |